Código QR (código de barras bidimensional)

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Abstract Background Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) o...

全面介紹

Na minha lista:
Principais autores: Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng
格式: Artigo
語言:Inglês
出版: BMC 2024-09-01
叢編:Arthritis Research & Therapy
主題:
Rheumatoid arthritis
Biosimilar pharmaceuticals
Tocilizumab
Treatment switching
在線閱讀:https://doi.org/10.1186/s13075-024-03375-w
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍